Phase II Study of Oxaliplatin in Combination With 5-Fu in 1st Line Treatment of Locally Advanced or Metastatic Squamous Cell Carcinoma of the Head and Neck
Phase II Study of Oxaliplatin in Combination With 5-Fu in 1st Line Treatment of Locally Advanced or Metastatic Squamous Cell Carcinoma of the Head and Neck
To evaluate the efficacy of first line oxaliplatin in combination with 5-fluorouracil (5-FU)
 in patients with advanced inoperable or metastatic head and neck cancer and to investigate
 the safety profile of this regimen in the above indication and consider other criteria of
 efficacy (clinical benefit, survival)
Inclusion Criteria:

 Patients aged 18-70 years, with inoperable locally advanced or metastatic squamous cell
 carcinoma of the head and neck (stage III-IV) histologically proven, no prior chemo and/or
 hormone therapy for metastatic disease or local recurrence (adjuvant or neo-adjuvant
 chemotherapy or radio-chemotherapy was allowed if finished since more than 6 months before
 inclusion and cisplatinum total dose used < or=to 300 mg/m² or carboplatinum total dose
 used < or=to 200mg/m²), at least 1 target lesion (measurable in 2 dimensions > or=to 20 mm
 on computed tomography (CT) or magnetic resonance imaging (MRI) evaluated < 15 days before
 start of study treatment, outside of irradiated fields),performance status (PS) < or =to 2
 World Health Organization (WHO), weight loss < 5% normal weight,hemoglobin > or =to 10
 g/dL, neutrophils > or =to 2000/mm3, platelets > or =to 100,000/mm3 , creatinine < or =to
 1.5 x upper limit of normal (ULN), bilirubin < or =to .5 x ULN, alanine amino-transferase
 (ALT)/aspartate amino-transferase (AST)< or =to 2.5 x ULN (5 x ULN if liver metastases),
 clotting: prothrombin time (PT) > or =to 60%. Written informed consent signed by patient
 and doctor prior to all study procedures -

 Exclusion Criteria:

 -